Dermatomyositis

Dermatomyositis is a rare autoimmune disease that mainly affects the skin and muscles. It is characterized by inflammation of muscles and skin, leading to muscle weakness and a distinctive rash. As a prominent player in rare disease research, our company is committed to supporting advancements in dermatomyositis research and therapeutic through our professional expertise and innovative solutions.

Overview of Dermatomyositis

Dermatomyositis is classified as a rare subtype of idiopathic inflammatory myopathies, with an estimated annual incidence of approximately 1 in 100,000 individuals, which arises from immune system dysregulation. One of the hallmark features of dermatomyositis is the presence of a unique rash that typically appears on the face, chest, and back, characterized by a reddish or purplish discoloration of the skin.

2-1-4-1 Histopathology of dermatomyositis.

Fig.1 Typical findings in dermatomyositis and immune-mediated necrotizing myopathy. (Kamperman, R. G., et al., 2022)

Pathogenesis of Dermatomyositis

The pathogenesis of dermatomyositis revolves around immune system dysfunction, viral infections, abnormal self-recognition by the immune system, and vascular lesions. The three may also be related to each other, intertwining in a complex web that influences disease progression and symptom severity.

Diagnostics Development of Dermatomyositis

Diagnostic advancements in dermatomyositis have identified specific biomarkers that aid in accurate disease detection and personalized therapeutic plans. Autoantibodies and molecular markers play a crucial role in predicting disease progression and guiding targeted therapies for affected individuals.

Anti-Mi-2 antibody
Anti-TIF1-γ antibody
OAS1/OAS2
Tenascin-C

Anti-MDA-5 antibody
Anti-HSC70 antibody
IFN
MX2

Anti-NXP2 antibody
Anti-SAE antibody
CitH3
Others

Therapeutics of Dermatomyositis

Small Molecule Drugs Therapy

Corticosteroids and immunosuppressive medications like azathioprine, methotrexate, and cyclophosphamide are utilized to manage symptoms and improve individual outcomes. Intravenous immunoglobulins have also shown efficacy in individuals.

Monoclonal Antibodies Therapy

Monoclonal antibodies such as rituximab (targeting CD20 antigen present on B-cells) can lead to the depletion of B cells and are effective in both myopathy and skin lesions in individuals with dermatomyositis.

Gene Therapy

Gene therapy regulates the expression of specific genes involved in the pathogenesis of dermatomyositis, or uses gene editing techniques, such as CRISPR/Cas9, to correct genetic mutations associated with dermatomyositis.

Our Services

Our company is equipped with expert teams and state-of-the-art resources to offer animal models and therapeutic development platforms, dedicated to driving progress in the diagnosis and therapeutic of dermatomyositis.

Platforms of Dermatomyositis Therapy Development

Animal Models of Dermatomyositis

The animal models provide valuable insights into the pathophysiology of dermatomyositis and help in the development of potential therapeutic strategies. Our company offers a variety of animal models of polymyositis to support your mechanism research and innovative therapy development.

Chemical-induced Models
Some chemical drugs can induce an animal immune response, leading to muscle inflammation and injury, mimicking the pathology of dermatomyositis.
Optional Models	C protein-induced model	Myosin-induced model
	Freund's adjuvant-induced model
Virus-induced Models
Viral infections in animal models induce muscle inflammation and autoimmunity. For example, coxsackievirus B infection in mice has been shown to induce muscle inflammation and immune responses similar to dermatomyositis.
Optional Models	Coxsackievirus-induced model
Genetically Engineered Models
Genetically engineered animal models lead to impaired immune systems by editing specific genes, promoting the development of dermatomyositis-like symptoms, including inflammatory muscle and skin damage.
Optional Models	MDA5-Transgenic model	SJL/J model
Optional Species	Mice, Rats, Zebrafish, Non-Human Primates, Others

Our company can provide a full range of services from research program development to therapeutic drug development to support your pharmacokinetics analysis and drug safety evaluation. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.

References

Kamperman, Renske G et al. "Pathophysiological Mechanisms and Treatment of Dermatomyositis and Immune Mediated Necrotizing Myopathies: A Focused Review." International journal of molecular sciences 23.8 (2022): 4301.
Xu, Shuyue et al. "Polymyositis and dermatomyositis biomarkers." Clinica chimica acta; international journal of clinical chemistry 547 (2023): 117443.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Related Disease Solutions